Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.

Marmouset V, Joris M, Merlusca L, Beaumont M, Charbonnier A, Marolleau JP, Gruson B.

Hematol Oncol. 2019 Aug 29. doi: 10.1002/hon.2671. [Epub ahead of print]

PMID:
31465531
2.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Jul 10. doi: 10.1158/1078-0432.CCR-18-3373. [Epub ahead of print]

PMID:
31292142
3.

Implication of Melanopsin and Trigeminal Neural Pathways in Blue Light Photosensitivity in vivo.

Marek V, Reboussin E, Dégardin-Chicaud J, Charbonnier A, Domínguez-López A, Villette T, Denoyer A, Baudouin C, Réaux-Le Goazigo A, Mélik Parsadaniantz S.

Front Neurosci. 2019 May 22;13:497. doi: 10.3389/fnins.2019.00497. eCollection 2019.

4.

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich PS, Milpied N, Turlure P, Nguyen S, Sirvent A, Bulabois CE, Berceanu A, Charbonnier A, Chevallier P, Bay JO, Neven B, Jubert C, Mohty M, Rubio MT, Peffault de Latour R.

Biol Blood Marrow Transplant. 2019 May 24. pii: S1083-8791(19)30324-6. doi: 10.1016/j.bbmt.2019.05.013. [Epub ahead of print]

PMID:
31129355
5.

Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.

Pagliardini T, Castagna L, Harbi S, Porta MD, Rey J, Fürst S, Bramanti S, Saillard C, Legrand F, Maisano V, Faucher C, Granata A, Hospital MA, Lining W, Weiller PJ, Calmels B, Charbonnier A, Lemarie C, Chabannon C, Vey N, Mokart D, Blaise D, Devillier R.

Biol Blood Marrow Transplant. 2019 May 22. pii: S1083-8791(19)30325-8. doi: 10.1016/j.bbmt.2019.05.014. [Epub ahead of print]

PMID:
31128325
6.

Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.

Garciaz S, Loschi M, De Masson A, Biard L, Mercier M, Tomowiak C, Delage J, Labussiere-Wallet H, Sibon D, Cassuto O, Borel C, Cornillon J, Nimubona S, Charbonnier A, Brice P, Socié G, Bouabdallah R, de Latour RP, de Fontbrune FS.

Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112. [Epub ahead of print] No abstract available.

PMID:
31014144
7.

Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).

Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, Huynh A, Mercier M, Bulabois CE, Lioure B, Chantepie S, Beguin Y, Bourhis JH, Malfuson JV, Clément L, Peffault de la Tour R, Cornillon J.

Bone Marrow Transplant. 2019 Feb 15. doi: 10.1038/s41409-019-0475-7. [Epub ahead of print]

PMID:
30770870
8.

Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia.

Zhao LP, Sicre De Fontbrune F, Contejean A, Abraham J, Terriou L, Chabrot C, Charbonnier A, Lengline E, Socié G, Peffault de Latour R.

Bone Marrow Transplant. 2019 Jul;54(7):1161-1163. doi: 10.1038/s41409-019-0452-1. Epub 2019 Jan 22. No abstract available.

PMID:
30670823
9.

Blue light exposure in vitro causes toxicity to trigeminal neurons and glia through increased superoxide and hydrogen peroxide generation.

Marek V, Potey A, Réaux-Le-Goazigo A, Reboussin E, Charbonnier A, Villette T, Baudouin C, Rostène W, Denoyer A, Mélik Parsadaniantz S.

Free Radic Biol Med. 2019 Feb 1;131:27-39. doi: 10.1016/j.freeradbiomed.2018.11.029. Epub 2018 Nov 27.

10.

Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.

Seguier J, Gelsi-Boyer V, Ebbo M, Hamidou Z, Charbonnier A, Bernit E, Durand JM, Harlé JR, Vey N, Schleinitz N.

Autoimmun Rev. 2019 Jan;18(1):36-42. doi: 10.1016/j.autrev.2018.07.009. Epub 2018 Nov 5. Review.

PMID:
30408583
11.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
12.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE.

Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3. No abstract available.

13.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

14.

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.

Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, André P, Paturel C, Zerbib R, Bennouna J, Salles G, Gonçalves A.

Oncotarget. 2018 Apr 3;9(25):17675-17688. doi: 10.18632/oncotarget.24832. eCollection 2018 Apr 3.

15.

Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients.

Saillard C, Elkaim E, Rey J, d'Incan E, Charbonnier A, Etienne A, Sannini A, Chow-Chine L, Bisbal M, Vey N, Mokart D.

Leuk Res. 2018 May;68:29-31. doi: 10.1016/j.leukres.2018.02.015. Epub 2018 Feb 28. No abstract available.

PMID:
29522988
16.

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

Devillier R, Legrand F, Rey J, Castagna L, Fürst S, Granata A, Charbonnier A, Harbi S, d'Incan E, Pagliardini T, Faucher C, Lemarie C, Saillard C, Calmels B, Mohty B, Maisano V, Weiller PJ, Chabannon C, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1449-1454. doi: 10.1016/j.bbmt.2018.02.002. Epub 2018 Feb 12.

17.

Impact of MICA and NKG2D polymorphisms in HLA-fully matched related and unrelated hematopoietic stem cell transplantation.

Apithy MJ, Charbonnier A, Desoutter J, Diouf M, Morel P, Garçon L, Marolleau JP, Guillaume N.

Bone Marrow Transplant. 2018 Jul;53(7):918-922. doi: 10.1038/s41409-017-0083-3. Epub 2018 Jan 29. No abstract available.

PMID:
29379169
18.

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Poiré X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, Nguyen S, Forcade E, Régny C, Bay JO, Bazarbachi A, Rohrlich PS, Huynh A, Farhi J, Marchand T, Malfuson JV, Pilorge S, Labussière-Wallet H, Renard C, Fornecker LM, Detrait M, Duléry R, Delage J, Ménard AL, Charbonnier A, Nelken B, Jubert C, Suarez F, de la Tour RP, Beguin Y, Schoemans H, Blaise D, Yakoub-Agha I.

Bone Marrow Transplant. 2018 Apr;53(4):400-409. doi: 10.1038/s41409-017-0018-z. Epub 2018 Jan 12.

19.

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N.

Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.

20.

[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Simon N, Coiteux V, Bruno B, Taque S, Charbonnier A, Souchet L, Vincent L, Yakoub-Agha I, Chalandon Y.

Bull Cancer. 2017 Dec;104(12S):S99-S105. doi: 10.1016/j.bulcan.2017.07.010. Epub 2017 Nov 23. Review. French.

PMID:
29173979
21.

Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.

Venton G, Courtier F, Charbonnier A, D'incan E, Saillard C, Mohty B, Mozziconacci MJ, Birnbaum D, Murati A, Vey N, Rey J.

Am J Hematol. 2018 Mar;93(3):330-338. doi: 10.1002/ajh.24973. Epub 2017 Dec 6.

22.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060
23.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

24.

Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.

Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B.

Br J Haematol. 2018 Jun;181(5):687-689. doi: 10.1111/bjh.14679. Epub 2017 Apr 25. No abstract available.

PMID:
28444730
25.

Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells.

Rey J, Fauriat C, Kochbati E, Orlanducci F, Charbonnier A, D'Incan E, Andre P, Romagne F, Barbarat B, Vey N, Olive D.

Front Immunol. 2017 Feb 2;8:64. doi: 10.3389/fimmu.2017.00064. eCollection 2017.

26.

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.

Sid S, Rey J, Charbonnier A, D'Incan E, Mohty B, Blaise D, Vey N.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):241-242. doi: 10.1016/j.clml.2016.10.002. Epub 2017 Jan 11. No abstract available.

PMID:
28196687
27.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.

Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2. No abstract available.

28.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

PMID:
28095277
29.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

30.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H.

Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111.

31.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

32.

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.

Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C.

Leuk Lymphoma. 2017 Aug;58(8):1880-1886. doi: 10.1080/10428194.2016.1263843. Epub 2016 Dec 2.

PMID:
27911138
33.

[Haploidentical hematopoietic stem cell transplantation: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)].

Nguyen S, Chalandon Y, Lemarie C, Simon S, Masson D, Dhedin N, Suarez F, Renaud B, Charbonnier A, Yafour N, François S, Duléry R, Blaise D, Yakoub-Agha I, Rubio MT.

Bull Cancer. 2016 Nov;103(11S):S229-S242. doi: 10.1016/j.bulcan.2016.09.007. Epub 2016 Nov 11. Review. French.

PMID:
27842860
34.

[Mission phagocytosis: how to fit the weapons to the target size].

Charbonnier A, Sannier G, Dupré S.

Med Sci (Paris). 2016 Jun-Jul;32(6-7):587-9. doi: 10.1051/medsci/20163206021. Epub 2016 Jul 12. French. No abstract available.

35.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
36.

Teaching NeuroImages: epilepsia partialis continua revealing PML after allogenic stem cell transplantation.

Andriuta D, Tir M, Perin B, Merle PE, Bryer-Le Breton C, Charbonnier A, Constans JM, Godefroy O.

Neurology. 2015 Aug 4;85(5):e53-4. doi: 10.1212/WNL.0000000000001804. No abstract available.

37.

Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase.

Colson P, Borentain P, Coso D, Motte A, Aurran-Schleinitz T, Charbonnier A, Stoppa AM, Chabannon C, Serrero M, Bertrand J, Barlesi F, Serratrice J, Portal I, Botta-Fridlund D, Tamalet C, Gerolami R.

Virology. 2015 Oct;484:354-63. doi: 10.1016/j.virol.2015.06.017. Epub 2015 Jul 14.

38.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.

Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G.

Leukemia. 2015 Jul;29(7):1496-501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.

PMID:
25676424
39.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Chevallier P, Huguet F, Raffoux E, Etienne A, Leguay T, Isnard F, Robillard N, Guillaume T, Delaunay J, Charbonnier A, Pigneux A, Peterlin P, Bené MC, Wegener WA, Goldenberg DM, Dombret H.

Haematologica. 2015 Apr;100(4):e128-31. doi: 10.3324/haematol.2014.120220. Epub 2014 Dec 31. No abstract available.

40.

A new data management system for the French National Registry of human alveolar echinococcosis cases.

Charbonnier A, Knapp J, Demonmerot F, Bresson-Hadni S, Raoul F, Grenouillet F, Millon L, Vuitton DA, Damy S.

Parasite. 2014;21:69. doi: 10.1051/parasite/2014075. Epub 2014 Dec 22.

41.

Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.

Devillier R, Bertoli S, Prébet T, Huguet F, Etienne A, Charbonnier A, Rey J, Delabesse E, D'Incan E, Huynh A, Blaise D, Récher C, Vey N.

Am J Hematol. 2015 Feb;90(2):E29-30. doi: 10.1002/ajh.23884. Epub 2014 Nov 19. No abstract available.

42.

Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.

Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D'Incan E, Charbonnier A, Blaise D, Mozziconacci MJ, Vey N.

Am J Hematol. 2015 Jan;90(1):E22-4. doi: 10.1002/ajh.23850. Epub 2014 Oct 18. No abstract available.

43.

Reply to J. Richter et al.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. No abstract available.

PMID:
25071119
44.

[Utilisation of immunosuppressants in the prevention of a graft versus host reaction: report by the SFGM-TC].

Belaiche S, Yafour N, Balcaen S, Beguin Y, Borel C, Bruno B, Godin S, Labussiere-Wallet H, Sanhamut N, Charbonnier A, de Berranger E, Konopacki-Potet J, Turlure P, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):197-203. doi: 10.1016/j.patbio.2014.05.010. Epub 2014 Jul 9. French.

45.

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors.

Castagna L, Crocchiolo R, Furst S, El-cheikh J, Esterni B, Granata A, Stoppa A, Boubdallah R, Coso D, Vey N, Charbonnier A, Lemarie C, Faucher C, Chabannon C, Blaise D.

Bone Marrow Transplant. 2014 Sep;49(9):1246-7. doi: 10.1038/bmt.2014.138. Epub 2014 Jul 7. No abstract available. Erratum in: Bone Marrow Transplant. 2014 Sep;49(9):1248.

PMID:
25000454
46.

[Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC].

Guillaume T, Porcheron S, Audat F, Bancillon N, Berceanu A, Charbonnier A, Dulery R, Edy N, El Cheikh J, Hermet E, Maurer N, Paul F, Konopacki-Potet J, Turlure P, Wallart A, Boulanger F, Dhédin N, Suarez F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):193-6. doi: 10.1016/j.patbio.2014.05.011. Epub 2014 Jul 1. French.

PMID:
24996843
47.

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

Devillier R, Harbi S, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Etienne A, Calmels B, Lemarie C, Prebet T, Granata A, Charbonnier A, Rey J, Chabannon C, Faucher C, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1560-5. doi: 10.1016/j.bbmt.2014.06.006. Epub 2014 Jun 14.

48.

Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study.

Paccou J, Merlusca L, Henry-Desailly I, Parcelier A, Gruson B, Royer B, Charbonnier A, Ursu D, Desailloud R, Garidi R, Kamel S, Sevestre H, Marolleau JP, Fardellone P, Damaj G.

Ann Oncol. 2014 Feb;25(2):481-6. doi: 10.1093/annonc/mdt560. Epub 2014 Jan 8.

PMID:
24401926
49.

Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia.

Saillard C, Etienne A, Charbonnier A, D'incan E, Rey J, Arnoulet C, Mozziconacci MJ, Blaise D, Vey N, Prebet T.

Leuk Lymphoma. 2014 Sep;55(9):2211-2. doi: 10.3109/10428194.2013.876497. Epub 2014 Jan 28. No abstract available.

PMID:
24354683
50.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

PMID:
24323036

Supplemental Content

Loading ...
Support Center